의료진소개
혈액내과 이유진 조교수
전문진료분야
급성백혈병, 만성골수성백혈병, 다발골수종, 조혈모세포이식, 골수이혈성증, 재생불량성 빈혈, 빈혈, 백혈구질환, 혈소판질환,응고질환, 각종 혈액질환, 발작성야간혈색소뇨증(PNH)
| 요일 | 월 | 화 | 수 | 목 | 금 |
|---|---|---|---|---|---|
| 오전 | 특수클리닉1 | 진료 | |||
| 오후 | 진료 | 진료 |
클리닉: 골수이식 클리닉
상세정보
학력
- 경북대학교 의학과 졸업(2007년)
- 경북대학교 의학과 석사(2011년)
- 경북대학교 의학과 박사(2018년)
경력
- 경북대학교 병원 인턴(2007년 3월 - 2008년 2월)
- 경북대학교 병원 내과 전공의(2008년 3월 - 20212년 2월)
- 경북대학교 병원 혈액종양내과 임상강사(2012년 3월 - 2013년 7월)
- 경북대학교 병원 혈액종양내과 임상조교수(2015년 3월 - 2019년 2월)
- 울산대학교 병원 혈액종양내과 임상조교수(2019년 3월 - 2020년 2월)
- 울산대학교 병원 혈액종양내과 조교수(2020년 3월 - 현재)
논문
1. Lee YJ, Kim KH, Min CK, et al. Benefits of additional cycles of bortezomib / thalidomide / dexamethasone ( VTD ) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma. Bone Marrow Transplant. 2019. doi:10.1038/s41409-019-0629-7
2. Park S, Baek DW, Sohn SK, et al. Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome. Clin Lymphoma, Myeloma Leuk. 2019;19(7):e367-e373. doi:10.1016/j.clml.2019.03.016
3. Seo M, Cha HJ, Kim M, et al. Clinical Utility of 18F-Florbetaben PET for Detecting Amyloidosis Associated With Multiple Myeloma. Clin Nucl Med. 2019;00(00):1. doi:10.1097/RLU.0000000000002699
4. Shin J, Jung J, Kihyun L, et al. Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone. Int J Hematol. 2019;109(1):79-90. doi:10.1007/s12185-018-2540-1
5. Kim T, Moon JH, Ahn J, et al. Next-generation sequencing – based posttransplant monitoring of acute myeloid leukemia identi fi es patients at high risk of relapse. Blood. 2018;132(15):1604-1613.
6. Lee YJ, Baek DW, Ahn J, et al. Impact of Consolidation Cycles Before Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission. Clin Lymphoma, Myeloma Leuk. 2018;18(12):e529-535. doi:10.1016/j.clml.2018.08.010
7. Ahn J-S, Kim H-J, Kim Y-K, et al. Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype. Oncotarget. 2018;9(4):4961-4968. doi:10.18632/oncotarget.23575
8. Baek DW, Lee YJ, Kim H, et al. Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts. Ann Hematol. 2018;97(12):2309-2317.
9. Lee K, Kim H, Ahn J, et al. A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome- positive chronic myeloid leukemia in chronic phase: ENESTKorea. Cancer Med. 2018;7(5):1814-1823. doi:10.1002/cam4.1450
10. Sohn SK, Moon JH, Lee YJ, et al. No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome. Korean J Intern Med. 2018;33(6):1194-1202.
11. Park H, Jin Y, Shin S, Lee J, Park S, Kim I. Which donor is better when a matched donor is not available domestically ? Comparison of outcomes of allogeneic stem cell transplantation with haploidentical and international donors in a homogenous ethnic population. Leuk Res. 2018;69(April):31-38. doi:10.1016/j.leukres.2018.04.002
12. Yoon JS, Lee YJ, Baek DW, et al. New synergistic efficacy of combination of romiplostim and steroid in refractory immune thrombocytopenia patients. Korean J Intern Med. 2018;33(2):435-437. doi:10.3904/kjim.2015.252
13. Byun JM, Koh Y, Shin D-Y, et al. BCR-ABL translocation as a favorable prognostic factor in elderly acute lymphoblastic leukemia patients in potent tyrosine kinase era. Haematologica. 2017;102(5):e187-190. doi:10.3324/haematol.2016.159988
14. Lee YJ, Park SW, Lee IH, et al. Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes. Ann Hematol. 2016;95(11):1795-1804. doi:10.1007/s00277-016-2759-y
15. Moon J-H, Lee B-H, Kim J-A, et al. Clinical impact of induction treatment modalities and optimal timing of radiotherapy for the treatment of limited-stage NK/T cell lymphoma. Leuk Res. 2016;49:80-87. doi:10.1016/j.leukres.2016.08.015
16. Sohn SK, Moon JH, Lee YJ, Park SW, Kim JY. Survey of experts on therapeutic policies and proposals for the optimal timing for allogeneic peripheral blood stem cell transplantation in transfusion-dependent patients with myelodysplastic syndrome-refractory anemia. Blood Res. 2016;51(1):44-49. doi:10.5045/br.2016.51.1.44
17. Moon JH, Lee YJ, Seo SK, et al. Outcomes of allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients with monosomal karyotypes. Acta Haematol. 2015;133(4):327-335. doi:10.1159/000365563
18. Shin HC, Seo J, Kang BW, et al. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy. Korean J Intern Med. 2014;29(6):785-792. doi:10.3904/kjim.2014.29.6.785
19. Lee S-WSJ, Kim JG, Lee S-WSJ, et al. Clinical implications of initial FDG-PET/CT in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Cancer Chemother Pharmacol. 2013;71(5):1201-1207. doi:10.1007/s00280-013-2114-0
20. Chae YS, Kim JG, Lee SJ, et al. A miR-146a polymorphism (rs2910164) predicts risk of and survival from colorectal cancer. Anticancer Res. 2013;33(8):3233-3240.
21. Lee YJ, Moon JH, Shin HC, et al. Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate. Int J Hematol. 2013;97(6):804-807. doi:10.1007/s12185-013-1326-8
22. Chae YS, Kim JG, Kang BW, et al. Functional polymorphism in the MicroRNA-367 binding site as a prognostic factor for colonic cancer. Anticancer Res. 2013;33(2):513-520. doi:33/2/513 [pii]
23. Kim JG, Lee SJ, Chae YS, et al. Association between Phosphorylated AMP-Activated Protein Kinase and MAPK3/1 expression and prognosis for patients with gastric cancer. Oncol. 2013;85(2):78-85. doi:10.1159/000351234
24. Choi JY, Kim JG, Lee YJ, et al. Prognostic impact of polymorphisms in the CASPASE genes on survival of patients with colorectal cancer. Cancer Res Treat. 2012;44(1):32-36. doi:10.4143/crt.2012.44.1.32
25. Kang BW, Jeong JY, Chae YS, et al. Phosphorylated AMP-Activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy. Cancer Chemother Pharmacol. 2012;70(5):735-741. doi:10.1007/s00280-012-1964-1
26. Kang BW, Kim JG, Chae YS, et al. Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer. Invest New Drugs. 2012;30(4):1671-1675. doi:10.1007/s10637-011-9729-y
27. Shin HC, Lee YJ, Moon JH, et al. Feasibility of Non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy. Korean J Intern Med. 2012;27(1):72-83. doi:10.3904/kjim.2012.27.1.72
28. Moon JH, Lee SJ, Lee YJ, et al. Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast. Ann Hematol. 2012;91(3):367-373. doi:10.1007/s00277-011-1321-1
29. Lee YJ. Prospective Randomization Trial of G-CSF-Primed Induction Regimen versus Standard Regimen in Patients with AML. Chonnam Med J. 2011;47:80-84.
30. Kim S, Moon J, Kim J, et al. associated with improved overall survival without increasing GVHD in reduced intensity conditioning allogeneic transplant recipients with clinically advanced disease. J Clin Apher. 2009;28(April 2013):349-355. doi:10.1002/jca
2. Park S, Baek DW, Sohn SK, et al. Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome. Clin Lymphoma, Myeloma Leuk. 2019;19(7):e367-e373. doi:10.1016/j.clml.2019.03.016
3. Seo M, Cha HJ, Kim M, et al. Clinical Utility of 18F-Florbetaben PET for Detecting Amyloidosis Associated With Multiple Myeloma. Clin Nucl Med. 2019;00(00):1. doi:10.1097/RLU.0000000000002699
4. Shin J, Jung J, Kihyun L, et al. Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone. Int J Hematol. 2019;109(1):79-90. doi:10.1007/s12185-018-2540-1
5. Kim T, Moon JH, Ahn J, et al. Next-generation sequencing – based posttransplant monitoring of acute myeloid leukemia identi fi es patients at high risk of relapse. Blood. 2018;132(15):1604-1613.
6. Lee YJ, Baek DW, Ahn J, et al. Impact of Consolidation Cycles Before Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission. Clin Lymphoma, Myeloma Leuk. 2018;18(12):e529-535. doi:10.1016/j.clml.2018.08.010
7. Ahn J-S, Kim H-J, Kim Y-K, et al. Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype. Oncotarget. 2018;9(4):4961-4968. doi:10.18632/oncotarget.23575
8. Baek DW, Lee YJ, Kim H, et al. Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts. Ann Hematol. 2018;97(12):2309-2317.
9. Lee K, Kim H, Ahn J, et al. A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome- positive chronic myeloid leukemia in chronic phase: ENESTKorea. Cancer Med. 2018;7(5):1814-1823. doi:10.1002/cam4.1450
10. Sohn SK, Moon JH, Lee YJ, et al. No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome. Korean J Intern Med. 2018;33(6):1194-1202.
11. Park H, Jin Y, Shin S, Lee J, Park S, Kim I. Which donor is better when a matched donor is not available domestically ? Comparison of outcomes of allogeneic stem cell transplantation with haploidentical and international donors in a homogenous ethnic population. Leuk Res. 2018;69(April):31-38. doi:10.1016/j.leukres.2018.04.002
12. Yoon JS, Lee YJ, Baek DW, et al. New synergistic efficacy of combination of romiplostim and steroid in refractory immune thrombocytopenia patients. Korean J Intern Med. 2018;33(2):435-437. doi:10.3904/kjim.2015.252
13. Byun JM, Koh Y, Shin D-Y, et al. BCR-ABL translocation as a favorable prognostic factor in elderly acute lymphoblastic leukemia patients in potent tyrosine kinase era. Haematologica. 2017;102(5):e187-190. doi:10.3324/haematol.2016.159988
14. Lee YJ, Park SW, Lee IH, et al. Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes. Ann Hematol. 2016;95(11):1795-1804. doi:10.1007/s00277-016-2759-y
15. Moon J-H, Lee B-H, Kim J-A, et al. Clinical impact of induction treatment modalities and optimal timing of radiotherapy for the treatment of limited-stage NK/T cell lymphoma. Leuk Res. 2016;49:80-87. doi:10.1016/j.leukres.2016.08.015
16. Sohn SK, Moon JH, Lee YJ, Park SW, Kim JY. Survey of experts on therapeutic policies and proposals for the optimal timing for allogeneic peripheral blood stem cell transplantation in transfusion-dependent patients with myelodysplastic syndrome-refractory anemia. Blood Res. 2016;51(1):44-49. doi:10.5045/br.2016.51.1.44
17. Moon JH, Lee YJ, Seo SK, et al. Outcomes of allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients with monosomal karyotypes. Acta Haematol. 2015;133(4):327-335. doi:10.1159/000365563
18. Shin HC, Seo J, Kang BW, et al. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy. Korean J Intern Med. 2014;29(6):785-792. doi:10.3904/kjim.2014.29.6.785
19. Lee S-WSJ, Kim JG, Lee S-WSJ, et al. Clinical implications of initial FDG-PET/CT in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Cancer Chemother Pharmacol. 2013;71(5):1201-1207. doi:10.1007/s00280-013-2114-0
20. Chae YS, Kim JG, Lee SJ, et al. A miR-146a polymorphism (rs2910164) predicts risk of and survival from colorectal cancer. Anticancer Res. 2013;33(8):3233-3240.
21. Lee YJ, Moon JH, Shin HC, et al. Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate. Int J Hematol. 2013;97(6):804-807. doi:10.1007/s12185-013-1326-8
22. Chae YS, Kim JG, Kang BW, et al. Functional polymorphism in the MicroRNA-367 binding site as a prognostic factor for colonic cancer. Anticancer Res. 2013;33(2):513-520. doi:33/2/513 [pii]
23. Kim JG, Lee SJ, Chae YS, et al. Association between Phosphorylated AMP-Activated Protein Kinase and MAPK3/1 expression and prognosis for patients with gastric cancer. Oncol. 2013;85(2):78-85. doi:10.1159/000351234
24. Choi JY, Kim JG, Lee YJ, et al. Prognostic impact of polymorphisms in the CASPASE genes on survival of patients with colorectal cancer. Cancer Res Treat. 2012;44(1):32-36. doi:10.4143/crt.2012.44.1.32
25. Kang BW, Jeong JY, Chae YS, et al. Phosphorylated AMP-Activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy. Cancer Chemother Pharmacol. 2012;70(5):735-741. doi:10.1007/s00280-012-1964-1
26. Kang BW, Kim JG, Chae YS, et al. Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer. Invest New Drugs. 2012;30(4):1671-1675. doi:10.1007/s10637-011-9729-y
27. Shin HC, Lee YJ, Moon JH, et al. Feasibility of Non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy. Korean J Intern Med. 2012;27(1):72-83. doi:10.3904/kjim.2012.27.1.72
28. Moon JH, Lee SJ, Lee YJ, et al. Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast. Ann Hematol. 2012;91(3):367-373. doi:10.1007/s00277-011-1321-1
29. Lee YJ. Prospective Randomization Trial of G-CSF-Primed Induction Regimen versus Standard Regimen in Patients with AML. Chonnam Med J. 2011;47:80-84.
30. Kim S, Moon J, Kim J, et al. associated with improved overall survival without increasing GVHD in reduced intensity conditioning allogeneic transplant recipients with clinically advanced disease. J Clin Apher. 2009;28(April 2013):349-355. doi:10.1002/jca